BOPI 03 BR/2024 REPERTOIRE NUMERIQUE 36 (74) S.C.P AKKUM, AKKUM & Associates, No. 1777, Rue 6.261, Auditorium Jean Paul II, Quartier Mbankolo, B.P. 4966, YAOUNDE (CM). (57) The invention relates to a vacuum tank (1) for a vacuum toilet, which tank comprises an inlet opening (2) which is located in a side wall of the tank and can be connected to the main drain (4) of a bowl (5) via a valve (3), and comprises an outlet opening (6) located at the deepest point for conveying the wastewater flow. The air in the tank can be vacuumed to a pressure below the atmospheric pressure via the outlet opening (6) or via additional openings in the vacuum tank (1). The vacuum tank (1) is subdivided into an upper volume (8) and a lower volume (9) by a separating element (7), the separating element (7) being arranged approximately at the height of the inlet opening (2) in the tank and forming a preferably helical, downwardly open groove (10) which extends across the periphery of the tank and, starting from the inlet opening (2), extends at least once around the horizontal periphery towards the lower volume (9). A through-opening (11) is located in the middle of the separating element (7) between the upper volume (8) and the lower volume (9). The invention also relates to a vacuum toilet having a vacuum tank (1) as described above. (11) 21470 Consulter le mémoire (51) A61P 35/00 (2018.01); C07F 9/53 (2018.01) (21) 1202300490 - PCT/IB2022/056248 (22) 06/07/2022 (30) IN n° 202121030204 du 06/07/2021 (54) Pyrimidine compounds for use as MAP4K1 inhibitors. (72) IYER Pravin (IN); DAS Sanji (IN); CHINNAPATTU Murugan (IN); CHAUDHARI Sachin (IN); SAINI Jagmohan (IN); MANDADI Sravan (IN); GOWDA Nagaraj (IN); DAHALE Dnyaneshwar (IN); PATIL Sandip (IN); KADLAG Nanasaheb (IN); MISRA Chandrasekhar (IN) et Priyanka PANGARE (IN) (73) Glenmark Specialty S.A., Avenue LeopoldRobert 37, 2300 LA CHAUX-DE-FONDS (CH) (74) Cabinet ÉKÉMÉ Lysaght SARL, B.P. 6370, YAOUNDE (CM). (57) The present disclosure is directed to compounds of formula (I) and pharmaceuticaliy acceptable salts thereof, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.
RkJQdWJsaXNoZXIy MTM1NDc3MA==